Why oral carbapenems are a game-changer for complicated UTIs
Complicated urinary tract infections (cUTIs) are increasingly caused by bacteria that resist common oral antibiotics, like fluoroquinolones and trimethoprim-sulfamethoxazole. This forces doctors to rely on IV antibiotics, which often require hospitalization or home infusion services. Oral carbapenems, like tebipenem, are designed to fill this gap: they are taken as a pill but have the broad-spectrum power of carbapenems, a class of antibiotics usually given intravenously. A 2022 phase 3 trial showed that oral tebipenem was non-inferior to IV ertapenem, meaning it worked just as well, with clinical cure rates of 93.1% vs. 93.6% [2]. This means patients could potentially be treated at home instead of in the hospital, which is a major practical benefit.
The need is urgent because resistance is common. In a 2018-2020 US surveillance study, about 15% of E. coli from UTIs met screening criteria for extended-spectrum beta-lactamase (ESBL) production, a key resistance mechanism [4]. ESBL-producing bacteria are often resistant to multiple oral options, making oral carbapenems a valuable last-line oral choice. The same study found tebipenem had consistent activity against these resistant strains, regardless of the specific resistance gene or bacterial lineage [4].
What the clinical trials actually show
The strongest evidence comes from two large phase 3 trials. The ADAPT-PO trial (2022) randomized 1,372 hospitalized patients with cUTI or acute pyelonephritis to oral tebipenem or IV ertapenem. The overall response (clinical cure plus microbiological eradication) was 58.8% for tebipenem vs. 61.6% for ertapenem, meeting the non-inferiority margin [2]. The PIVOT-PO trial (2026) compared oral tebipenem to IV imipenem-cilastatin in 929 patients, finding overall response rates of 58.5% vs. 60.2%, also non-inferior [1]. Both trials showed similar safety profiles, with diarrhea and headache being the most common side effects [1][2].
These trials also showed that oral tebipenem works against ESBL-producing bacteria. In ADAPT-PO, clinical cure rates for ESBL-positive Enterobacterales were 87.6% for tebipenem vs. 95.3% for ertapenem, a difference that was not statistically significant [3]. In PIVOT-PO, treatment effects were comparable in participants with ESBL-positive pathogens [1]. This is important because ESBL-producing bacteria are a major cause of resistance in cUTIs, and oral options are limited.
Caveats: not a magic bullet, but a valuable tool
While the results are promising, there are important caveats. The overall response rates in these trials (around 58-60%) are lower than clinical cure rates (over 90%) because they include microbiological eradication, which often fails due to asymptomatic bacteriuria (bacteria in the urine without symptoms) [2][3]. This is a common phenomenon in cUTI trials and does not necessarily mean treatment failure in practice.
Another consideration is the risk of resistance. A 2022 in vitro study found that tebipenem has a low propensity for spontaneous resistance, similar to other carbapenems, but resistance can still emerge through mutations that reduce bacterial permeability [5]. This underscores the need for antimicrobial stewardship—using these drugs judiciously to preserve their effectiveness. A 2025 study from Japan also emphasized careful use to prevent resistance [6].
Finally, oral carbapenems are not yet widely available. Tebipenem pivoxil hydrobromide is investigational in the US, though it has been used in Japan for years [6]. As they become more available, they could reduce hospital stays and IV line complications, but their role in routine practice will depend on local resistance patterns and stewardship policies.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2026, 2 from 2024 or later, 1 in Q1 journals, collectively cited 71 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
173. Oral Tebipenem Pivoxil Hydrobromide versus Intravenous Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study
In the PIVOT-PO phase 3 trial, oral tebipenem was non-inferior to IV imipenem-cilastatin for cUTI/AP, with overall response 58.5% vs 60.2%, and comparable efficacy in ESBL-positive infections.
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
The ADAPT-PO phase 3 trial showed oral tebipenem non-inferior to IV ertapenem, with clinical cure 93.1% vs 93.6% and overall response 58.8% vs 61.6%.
222. Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide
In ADAPT-PO, clinical cure for ESBL-positive Enterobacterales was 87.6% for tebipenem vs 95.3% for ertapenem, with similar microbiological response rates.
1254. Molecular Epidemiology of <i>Escherichia coli</i> Causing Urinary Tract Infections in United States and <i>in vitro</i> Activity of Tebipenem, Including Against Strain Lineage and Resistant subsets (2018-2020)
US surveillance (2018-2020) found ~15% of E. coli from UTIs were ESBL-positive, mostly ST131, and tebipenem showed consistent activity against all subsets.
150. Low Propensity for Development of Spontaneous <i>In Vitro</i> Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
In vitro studies showed tebipenem has a low frequency of spontaneous resistance, similar to ertapenem and meropenem, with resistance mutations affecting porins.
Antimicrobial activity of tebipenem to Escherichia coli isolates from outpatients with complicated urinary tract infections
A 2019 Japanese study found tebipenem had MIC90 ≤0.03 μg/mL against both non-ESBL and ESBL-producing E. coli from cUTIs, comparable to IV carbapenems.